Krystal Biotech, Inc. (KRYS - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $22.00 to $23.30 in the past one-month time frame.
The move came after the company announced the opening of a cGMP facility for the clinical and commercial production of its lead product KB103, which is useful for treatment of people with dystrophic epidermolysis bullosa (DEB).
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Krystal currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Krystal Biotech, Inc. Price
Investors interested in the Medical - Biomedical and Genetics industry may consider Celcuity Inc. (CELC - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is KRYS going up? Or down? Predict to see what others think: Up or Down
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>